Teva to Buy Merck KGaA’s Generics?

Teva Pharmaceutical Industries (Petach Tikva, Israel) is likely to be selected to acquire Merck KGaA’s generic pharmaceutical business, sources say. Merck KGaA invited offers for the business but says it has not made a final decision to divest. Aggressive bidding had pushed the price of the generics business up to €4 billion-€5 billion ($5.5 billion-$6.8 billion) by the close of a revised round of bids on April 30, sources add. The other bidders are reportedly Mylan (Canonsburg, PA), and a joint offer by private equity firms Apax Partners and Bain...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers